Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulinastatin in Inhalation Lung Injury
NCT01287806Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Feb 2011
- Primary completion
- Dec 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ulinastatin in Inhalation injury (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: All Cause Mortality. Status: unknown.
02
Drugs
ulinastatin
03
Conditions
Inhalation injury
Beyond the preview
Go deeper on NCT01287806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01287806.